Enfuvirtide Acetate (T-20)
Псевдоним:Fuzeon
Последовательность:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Кас Нет. : 159519-65-0
Молекулярная формула : C204H301N51O64
Молекулярный вес : 4492
Чистота (ВЭЖХ) : 98.0%мин.
Появление : White to off-white amorphous solid
Одиночная примесь (ВЭЖХ) : 0.5%Макс
Аминокислотный состав : ±10% of theoretical
Содержание пептидов (Н%) : ≥80.0%
Содержание воды (Карл Фишер) : ≤8,0%
TrifluoroAcetate Content(HPIC) : ≤12.0%
MS (ЭСИ) : Consistent
Массовый баланс : 95.0~105,0%
Оценка : Фармацевтический класс
Хранилище: Закрыто, ниже 2 ~ 8℃ preservation
Использование : Treatment option for patients suffering from HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (ГОСТИНИЦА) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
